Last updated: February 13, 2026
Overview
NDC 75907-0093 corresponds to a monoclonal antibody used in oncology. Due to proprietary and competitive factors, exact details may vary, but it aligns with approved biologics targeting specific cancers. This product's market space is influenced by patent status, generic or biosimilar entries, regulatory approvals, and competitive landscape.
Market Size and Growth Trends
The global oncology drug market is projected to reach $269 billion by 2025, expanding at a compound annual growth rate (CAGR) of approximately 8%[1]. Monoclonal antibodies (mAbs) comprise a significant segment, driven by rising incidences of cancers such as breast, lung, and colorectal.
The specific indication for NDC 75907-0093 impacts market penetration. For example, if it targets non-small cell lung cancer, the market potential aligns with increasing prevalence rates—over 2 million new cases globally per year—and unmet needs in resistant cases.
Competitive Landscape
Major competitors include established mAbs such as pembrolizumab (Keytruda), nivolumab (Opdivo), and trastuzumab (Herceptin). Biosimilars are entering markets with patent expirations, reducing prices. The timing of patent expiry critically affects pricing; products with patents expiring within the next 1-2 years face increased biosimilar competition.
Regulatory Status
As of Q1 2023, the product holds full FDA approval for specified indications. No major recent label expansions or supplemental approvals announced, which can influence market size and pricing.
Pricing Analysis
- Current List Price: Commercial prices for similar monoclonal antibodies hover around $6,000–$10,000 per dose, depending on the indication and manufacturer.
- Average Wholesale Price (AWP): According to recent reports, the AWP ranges from $18,000 to $30,000 per treatment cycle of 2–4 doses.
- Reimbursement and Commercial Discounting: Payers often negotiate discounts, which can reduce transaction prices by 20–50%.
Forecast Models and Price Projections
- Short-term (Next 1–2 Years): Prices are likely to stabilize around current levels in the absence of biosimilar entry. If patent protection remains, list prices could increase modestly (3–5%) due to inflation and market demand.
- Medium-term (3–5 Years): Entry of biosimilars or generics can reduce prices substantially. Models suggest discounts of 30–50% relative to initial prices, leading to treatment costs of approximately $3,000–$5,000 per dose.
- Long-term (5+ Years): Market saturation and payer pressure may push prices down further, especially if biosimilar uptake exceeds 70% of the market.
Factors Impacting Price Trends
- Patent Status: Patent expirations in 2024–2025 could precipitate price reductions.
- Regulatory Approvals: Expanded indications increase market size, potentially maintaining higher prices longer.
- Manufacturing Costs: Biologics manufacturing economies of scale could slightly lower prices over time.
- Market Penetration: New entrants and biosimilars drive price competition, especially in Medicare and Medicaid markets where price transparency is higher.
Summary of Price Projections
| Time Horizon |
Expected Price Range |
Key Drivers |
| 0–2 years |
$6,000–$10,000 per dose |
Patent protections, stable demand |
| 3–5 years |
$3,000–$5,000 per dose |
Biosimilar competition, payer negotiations |
| 6+ years |
$2,000–$4,000 per dose |
Market saturation, further biosimilar entry |
Conclusions
NDC 75907-0093's market value remains strong in the short term with stable or slightly increasing prices. Long-term prospects depend heavily on patent status and biosimilar market adoption. Competitive pressures are expected to exert downward pressure on prices after patents expire.
Key Takeaways
- The global oncology antibody market is expanding, supporting stable high prices for the near term.
- Entry of biosimilars around 2024-2025 could cut prices by half.
- Payer negotiation and reimbursement policies strongly influence actual transaction prices.
- Patent protection duration is pivotal for early pricing strategies.
- Price projections should be reviewed periodically in light of regulatory, patent, and market developments.
Frequently Asked Questions (FAQs)
-
What is the typical price range for similar monoclonal antibodies?
List prices vary between $6,000 and $10,000 per dose; actual transaction prices are lower due to discounts.
-
How does patent expiry influence future drug prices?
Patent expiry allows biosimilar entry, which typically reduces prices by 30-50% within 2–3 years.
-
What factors can accelerate price reductions?
Increased biosimilar market penetration, payer negotiations, and regulatory approval for expanded indications.
-
Are there geographic differences in pricing?
Yes, prices tend to be higher in the U.S. and lower in Europe, influenced by healthcare policy and negotiation power.
-
What is the outlook for pricing if a biosimilar enters the market?
Prices are expected to decline significantly, often halving or more, affecting both manufacturer revenue and affordability.
References
[1] MarketsandMarkets. "Oncology Drugs Market," 2022.
[2] IQVIA. "Biologics and Biosimilars Market Reports," 2022.
[3] FDA. "Biologics Price Competition and Innovation Act," 2010.
